HBeAg testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women
The Journal of Infection in Developing Countries · 2023
DOI: 10.3855/jidc.17516 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Minh Ngoc Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pasteur Institute in Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Pregnancy Complications, Infectious, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Using tenofovir disoproxil fumarate (TDF) is recommended in the 3rd trimester for pregnant women with HBV DNA ≥ 200,000 IU/mL to prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV). However, HBV DNA quantification is unavailable in many resource-limited areas worldwide, hence prophylaxis is often missed. The aim of this study was to determine whether HBeAg or qHBsAg is a better alternative to HBV DNA testing in HBV-infected pregnant women. Methodology: In this prospective cohort study, pregnant women with HBV infection were recruited in 3 hospitals from October 2019 to November 2020. Socio-demographic and clinical data were collected. Blood samples were taken for qHBsAg and HBV DNA testing. HBeAg results were collected from the medical records of the participants who visited a doctor during the study.
Results
465 pregnant women met the study criteria. 41.9% were HBeAg positive, 33.3% had high qHBsAg levels (> 104 IU/mL), 38.3% had high HBV DNA levels (≥ 200,000 IU/mL). Pregnant women with high qHBsAg levels were 27 times more likely to have high HBV DNA levels (aOR = 27.0, 95% CI: 11.1-65.5, p < 0.001). Participants who were HBeAg positive were 57.5 times more likely to have high HBV DNA levels (aOR = 57.5, 95% CI: 23.0-140.0, p < 0.001). The sensitivity of qHBsAg and HBeAg was 80% and 94%, respectively; and specificity was 95% and 90%, respectively.
Conclusions
HBeAg testing should be considered over qHBsAg assay as an alternative to HBV DNA assay because of its technical simplicity, lower cost, and fewer missed treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pasteur Institute in Ho Chi Minh City, Vietnam.
- University of Medicine Pham Ngoc Thach, Ho Chi Minh City, Vietnam.
- Can Tho Department of Health, Vietnam.
Zitieren
APA
Nguyen, M. N., Nguyen, T. T. H., Pham, T. D. H., Khuu, V. N., Hoang, Q. C., Nguyen, V. T., & Tran, N. H. (2023). HBeAg testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.17516
Vancouver
Nguyen MN, Nguyen TTH, Pham TDH, Khuu VN, Hoang QC, Nguyen VT, et al. HBeAg testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.17516
BibTeX
@article{Nguyen2023,
author = {Nguyen, Minh Ngoc and Nguyen, Thi Thu Huong and Pham, Tran Dieu Hien and Khuu, Van Nghia and Hoang, Quoc Cuong and Nguyen, Vu Thuong and Tran, Ngoc Huu},
title = {HBeAg testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women},
journal = {The Journal of Infection in Developing Countries},
year = {2023},
doi = {10.3855/jidc.17516}
}
EUVIMED